Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey.


Journal

The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984

Informations de publication

Date de publication:
09 2022
Historique:
accepted: 09 02 2022
pubmed: 3 3 2022
medline: 26 10 2022
entrez: 2 3 2022
Statut: ppublish

Résumé

To generate initial data on the frequency and effect of symptomatic adverse events (AEs) associated with rheumatoid arthritis (RA) drug therapy from the patient perspective. We conducted an exploratory online survey asking patients with RA to indicate whether they currently or had ever experienced the 80 different symptomatic AEs included in the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Results were summarized to report their frequency, and regression models were used to estimate their associations with RA medication use and overall bother. The 560 patients who completed the survey and reported taking ≥ 1 RA medication (disease-modifying antirheumatic drugs [DMARDs], steroids, nonsteroidal antiinflammatory drugs [NSAIDs]), had a mean disease duration of 8 years, and were on a wide range of DMARDs. The number of symptomatic AEs experienced in the past 7 days was none (6%), 1-10 (28%), 11-20 (28%), and > 20 (38%). Overall, most participants reported that side effects bothered them somewhat (28%), quite a bit (24%), or very much (15%). In multivariable regression analyses, current prednisone and NSAID use were associated with the greatest number of current side effects (26 and 22, respectively). Many of the strongest associations between current symptomatic AEs and medication use aligned with known side effect profiles. In this exploratory online survey, patients with RA reported frequent symptomatic AEs with their medications that are bothersome. Further work is needed to develop and validate a measure for use in patients with rheumatic disease.

Identifiants

pubmed: 35232804
pii: jrheum.210688
doi: 10.3899/jrheum.210688
doi:

Substances chimiques

Prednisone VB0R961HZT
Antirheumatic Agents 0
Anti-Inflammatory Agents, Non-Steroidal 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

998-1005

Subventions

Organisme : CIHR
ID : FRN 156267
Pays : Canada

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2022 by the Journal of Rheumatology.

Auteurs

Glen S Hazlewood (GS)

G.S. Hazlewood, MD, PhD, Associate Professor, Department of Medicine, and Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Richmond, British Columbia, Canada; gshazlew@ucalgary.ca.

Orit Schieir (O)

O. Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario, Canada.

Vivian Bykerk (V)

V. Bykerk, MD, Professor, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA.

Kamso Mujaab (K)

K. Mujaab, MSc, P.M. Hull, PGCE PGDip (BJTC), Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Peter Tugwell (P)

P. Tugwell, MD, Professor, Department of Medicine, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

George Wells (G)

G. Wells, PhD, Professor, Cardiovascular Research Methods Centre, Ottawa Heart Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.

Dawn Richards (D)

D. Richards, PhD, L. Proulx, B.Com, Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada.

Laurie Proulx (L)

D. Richards, PhD, L. Proulx, B.Com, Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada.

Pauline M Hull (PM)

K. Mujaab, MSc, P.M. Hull, PGCE PGDip (BJTC), Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Susan J Bartlett (SJ)

S.J. Bartlett, PhD, Professor, Arthritis Research Canada, Richmond, British Columbia, Department of Medicine, McGill University, and Research Institute-McGill University Health Center, McGill University, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH